Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NYSE:NVS OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$247.55-2.5%$238.64$159.80▼$269.43$611.07B0.248.19 million shs10.54 million shsNVSNovartis$150.89+0.4%$151.11$112.34▼$170.46$286.91B0.452.00 million shs1.76 million shsRHHBYRoche$51.18+2.0%$51.32$37.51▼$60.85$319.55B0.51.80 million shs961,289 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-1.60%-5.10%+5.46%+6.33%+61.68%NVSNovartis-1.89%-4.07%-1.68%-1.06%+24.28%RHHBYRoche-0.67%-3.85%-2.88%-1.63%+24.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$247.55-2.5%$238.64$159.80▼$269.43$611.07B0.248.19 million shs10.54 million shsNVSNovartis$150.89+0.4%$151.11$112.34▼$170.46$286.91B0.452.00 million shs1.76 million shsRHHBYRoche$51.18+2.0%$51.32$37.51▼$60.85$319.55B0.51.80 million shs961,289 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-1.60%-5.10%+5.46%+6.33%+61.68%NVSNovartis-1.89%-4.07%-1.68%-1.06%+24.28%RHHBYRoche-0.67%-3.85%-2.88%-1.63%+24.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.74Moderate Buy$261.705.72% UpsideNVSNovartis 2.31Hold$141.20-6.42% DownsideRHHBYRoche 2.36Hold$51.500.63% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, RHHBY, and NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026JNJJohnson & Johnson Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$260.007/13/2026JNJJohnson & Johnson TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$250.00 ➝ $300.007/13/2026JNJJohnson & Johnson Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$265.00 ➝ $287.007/10/2026JNJJohnson & Johnson Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$254.00 ➝ $263.007/8/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$283.00 ➝ $284.007/8/2026JNJJohnson & Johnson CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $298.007/6/2026JNJJohnson & Johnson HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$290.007/6/2026RHHBYRoche HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/26/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$270.006/26/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$266.00 ➝ $270.006/15/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$94.19B6.33$13.77 per share17.98$33.85 per share7.31NVSNovartis$54.53B5.28$10.78 per share14.00$22.04 per share6.85RHHBYRoche$76.45B4.26$3.67 per share13.93$7.18 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$26.80B$8.6528.6219.602.4221.83%32.60%13.29%7/15/2026 (Estimated)NVSNovartis$13.98B$6.9821.6215.512.5924.87%38.82%15.16%7/21/2026 (Estimated)RHHBYRoche$15.55BN/AN/A15.373.97N/AN/AN/A7/23/2026 (Estimated)Latest JNJ, RHHBY, and NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2026N/ARHHBYRoche$1.59N/AN/AN/A$38.34 billionN/A7/21/2026Q2 2026NVSNovartis$2.17N/AN/AN/A$14.15 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.85$2.90+$0.05$2.27$25.02 billion$25.31 billion4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.362.17%+5.25%61.97%64 YearsNVSNovartis$3.082.04%+5.28%44.13%N/ARHHBYRoche$0.971.90%N/AN/AN/ALatest JNJ, RHHBY, and NVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/15/2026JNJJohnson & Johnsonquarterly$1.342.17%8/25/20268/25/20269/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.461.030.77NVSNovartis0.960.850.65RHHBYRoche0.721.381.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVSNovartis13.12%RHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVSNovartis0.01%RHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableRHHBYRoche103,2496.37 billionN/ANot OptionableJNJ, RHHBY, and NVS HeadlinesRecent News About These CompaniesRHHBY's Gazyva Gets FDA Priority Review for Label ExpansionJuly 15 at 1:10 PM | zacks.comRoche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitisJuly 14 at 9:17 AM | manilatimes.netMIonis extends losses as Roche scraps two partnered studiesJuly 10, 2026 | seekingalpha.comTeva, Polpharma ink licensing pact for biosimilar targeting Roche’s OcrevusJuly 9, 2026 | seekingalpha.comRoche receives CE Mark for blood test to identify tuberculosis infectionJuly 9, 2026 | manilatimes.netMGenentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAICJuly 7, 2026 | joplinglobe.comJRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | finance.yahoo.comGenentech and Roche Present New Data in Alzheimer's Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAICJuly 7, 2026 | businesswire.comRoche presents new data in Alzheimer's disease from across its integrated pharmaceutical and diagnostics portfolio at AAICJuly 7, 2026 | globenewswire.comRoche Reports Positive Results From Head-to-Head Study on NSCLC DrugJuly 3, 2026 | zacks.com[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung ...July 2, 2026 | finance.yahoo.comRoche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage TrialJuly 2, 2026 | wsj.comRoche Gets FDA Priority Review for Enspryng in Thyroid Eye DiseaseJune 30, 2026 | zacks.comFDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)June 30, 2026 | uk.finance.yahoo.comRoche announces the launch of AXELIOS 1, a transformative next-generation sequencing platformJune 29, 2026 | taiwannews.com.twTRoche launches Axelios gene sequencer in a bid to loosen Illumina's gripJune 29, 2026 | reuters.comRoche Acquires IQuumJune 25, 2026 | finance.yahoo.comEXEL Down on Colorectal Cancer Study Data on ZanzalintinibJune 23, 2026 | zacks.comTG Therapeutics stock is on a hot streak: Why it's up 79% and climbingJune 18, 2026 | msn.comFDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCLJune 18, 2026 | zacks.com3 ETFs to Avoid as Oil Shock Hits Markets (RHHBY)...March 12, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityBy Thomas Hughes | July 15, 2026JNJ, RHHBY, and NVS Company DescriptionsJohnson & Johnson NYSE:JNJ$247.55 -6.30 (-2.48%) Closing price 03:59 PM EasternExtended Trading$247.65 +0.10 (+0.04%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novartis NYSE:NVS$150.89 +0.53 (+0.36%) Closing price 03:59 PM EasternExtended Trading$151.87 +0.98 (+0.65%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Roche OTCMKTS:RHHBY$51.18 +1.02 (+2.03%) As of 03:59 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
